C ardiovascular disease and heart failure remain a major cause of mortality worldwide with tremendous socioeconomic consequences (1) . In the Western world, coronary artery disease and subsequent myocardial infarction injury are the leading disease sequelae contributing to heart failure, which is characterized by progressive ventricular stiffening, remodeling and fibrosis, myocyte dropout, reduced contractility, and rhythm disturbances (2) . An underlying progressive fibrotic response appears to worsen cardiac function, predispose to arrhythmia, and limit any chances for minor regenerative efforts within the heart (3). Cardiac fibroblasts (CF) are presumed to be the major mediators of physiological scar formation after acute myocardial infarction that prevents wall rupture, as well as the mediators of long-standing and progressive fibrotic remodeling during heart failure. CF become activated by injury or long-standing disease during which they can synthesize and deposit collagen and other extracellular matrix proteins, as well as affect ventricular wall and septal remodeling through their newly acquired contractile activity (4).
The concept of identifying novel antifibrotic therapies that target select functions of the activated fibroblast has been an ongoing research goal (5), although effective agents are still lacking.
Until recently, a major limitation in understanding the pathologic fibrotic response has been our inability to identify the origin and molecular characteristics of CF. However, in the past few years a number of genetic approaches in mouse models have begun to reveal the origins of the CF and the central molecular effector pathways that mediate their activation (6) (7) (8) (9) .
These studies collectively determined that CF residing within the adult heart are a developmentally traceable cell-type differing from many other tissue resident fibroblasts (9,10). More specifically, diseaserelevant CF in the adult mouse heart are derived from a developmental epicardial origin of cells best defined by the molecular markers TCF21, TBX18, and WT1 (10, 11) , and when activated during disease they uniformly express the marker periostin (6) and other contractile genes such as smooth muscle a-actin (12) .
Far less is understood of fibroblast origins and molecular characteristics in the human heart, during both development and disease processes in adults.
Indeed past studies have suggested that fibroblast characteristics can vary between large and small mammals (and humans) when compared even within the same tissues (13, 14) . Therefore, more studies of human-derived cardiac fibroblasts are needed, espe- 
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